Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Brentuximab vedotin Monotherapy, 2022, version number 5, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy	1
Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).	1
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)	1
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	CD30 +	Cutaneous T-cell Lymphoma	Brentuximab Vedotin
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Brentuximab Vedotin
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Brentuximab Vedotin
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Brentuximab Vedotin